Future investigations may focus on further replication of these findings and the clinical relevance of retinol and RBP4 levels as potential therapeutic targets for risk reduction or markers of CVD and T2D risk in the identified subgroups. The gene discussed is RBP4; the disease is type 2 diabetes mellitus.